Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 3:36 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1321–1344 of 9,145 matching trials from the live ClinicalTrials.gov search.

Filters: Rochester, Minnesota Clear all

Conditions: Ulcerative Colitis (UC)
Interventions: TD-1473 Dose A, TD-1473 Dose B, TD-1473 Dose C; Drug
Lead sponsor: Theravance Biopharma; Industry
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 36
States / cities: Chula Vista, California • Lancaster, California • Orange, California + 32 more

Conditions: Myelodysplastic Syndrome, Iron Overload
Interventions: Deferasirox; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 42
States / cities: Birmingham, Alabama • Phoenix, Arizona • Concord, California + 36 more

Conditions: Polycystic Ovary Syndrome
Interventions: Metformin; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Coronary Artery Disease
Interventions: CADence; Diagnostic Test
Lead sponsor: AUM Cardiovascular, Inc.; Industry
Eligibility: 22 Years and older
Enrollment: 1,014 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 24
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 18 more

Conditions: Rheumatoid Arthritis
Interventions: Certolizumab Pegol (CZP), Adalimumab (ADA), Methotrexate (MTX); Biological · Drug
Lead sponsor: UCB Pharma SA; Industry
Eligibility: 18 Years and older
Enrollment: 915 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 62
States / cities: Birmingham, Alabama • Tuscaloosa, Alabama • Tucson, Arizona + 56 more

Conditions: Heart Failure
Interventions: Not listed
Lead sponsor: Medtronic; Industry
Eligibility: Not listed
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2022
U.S. locations: 102
States / cities: Birmingham, Alabama • Anchorage, Alaska • Chandler, Arizona + 99 more

Conditions: Complex Sleep Apnea Syndrome
Interventions: VPAP Adapt SV; Device
Lead sponsor: ResMed; Industry
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 6
States / cities: Phoenix, Arizona • Chicago, Illinois • Skokie, Illinois + 3 more

Conditions: Short Bowel Syndrome
Interventions: Glepaglutide; Drug
Lead sponsor: Zealand Pharma; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 4
States / cities: Washington D.C., District of Columbia • Rochester, Minnesota • Omaha, Nebraska + 1 more

Conditions: Breast Cancer
Interventions: Positron emission tomography (PET), Trastuzumab, Pertuzumab; Procedure · Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2027
U.S. locations: 10
States / cities: Birmingham, Alabama • Washington D.C., District of Columbia • Indianapolis, Indiana + 6 more

Conditions: Healthy
Interventions: 0.4mU Insulin followed by withdrawal period followed by 0.8mU study, 0.8mU Insulin followed by withdrawal period followed by 0.4mU study; Drug
Lead sponsor: Adrian Vella; Other
Eligibility: 18 Years to 40 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Lung Cancer, Radiation Toxicity
Interventions: Cetuximab, Carboplatin, Paclitaxel, 60 Gy RT, 74 Gy RT; Biological · Drug · Radiation
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: 18 Years and older
Enrollment: 544 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2022
U.S. locations: 207
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 170 more

Conditions: Influenza
Interventions: Influenza VLP Vaccine, TIV; Biological
Lead sponsor: Novavax; Industry
Eligibility: 60 Years and older
Enrollment: 467 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 6
States / cities: Pembroke Pines, Florida • Rochester, Minnesota • Providence, Rhode Island + 3 more

Conditions: Thumb Carpometacarpal Joint Osteoarthritis
Interventions: Platelet-rich plasma; Biological
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 80 Years
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Prostate Adenocarcinoma, Stage I Prostate Adenocarcinoma AJCC v7, Stage II Prostate Adenocarcinoma AJCC v7, Stage III Prostate Adenocarcinoma AJCC v7
Interventions: Hypofractionated Radiation Therapy, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Radiation Therapy; Radiation · Other
Lead sponsor: NRG Oncology; Other
Eligibility: 18 Years and older · Male only
Enrollment: 296 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 229
States / cities: Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 188 more

Conditions: Lumbar Degenerative Disc Disease
Interventions: SIFS graft containment device; Device
Lead sponsor: Spineology, Inc; Industry
Eligibility: 21 Years to 80 Years
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 10
States / cities: DeLand, Florida • Shreveport, Louisiana • Thibodaux, Louisiana + 7 more

Conditions: Colostomy
Interventions: intraperitoneal or extraperitoneal colostomy; Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1988 – 2013
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Prostate Cancer
Interventions: Irreversible Electroporation; Device
Lead sponsor: Angiodynamics, Inc.; Industry
Eligibility: 50 Years and older · Male only
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 17
States / cities: Orange, California • Aurora, Colorado • Gainesville, Florida + 11 more

Conditions: Kidney Transplant Rejection
Interventions: Not listed
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 3
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota

Conditions: Cardiac Sarcoidosis, Sarcoidosis of the Heart, Sarcoidosis With Myocarditis, Sarcoidosis, Cardiac
Interventions: Exosome Analysis; Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Eosinophilic Gastritis, Eosinophilic Gastroenteritis, Eosinophilic Duodenitis
Interventions: AK002; Drug
Lead sponsor: Allakos Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 17
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Ventura, California + 14 more

Conditions: Eosinophilic Gastrointestinal Disorders (EGIDs), Eosinophilic Esophagitis, Eosinophilic Gastritis, Eosinophilic Gastroenteritis, Eosinophilic Colitis
Interventions: Not listed
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 3 Years and older
Enrollment: 1,350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2051
U.S. locations: 19
States / cities: Phoenix, Arizona • Rogers, Arkansas • San Diego, California + 14 more

Conditions: Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
Interventions: Ficerafusp alfa, Pembrolizumab (KEYTRUDA®), Placebo; Drug
Lead sponsor: Bicara Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 650 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 55
States / cities: Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 41 more

Conditions: FGFR2 Gene Fusion/Rearrangement, Other Solid Tumors, Adult
Interventions: Lirafugratinib; Drug
Lead sponsor: Elevar Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 8
States / cities: Phoenix, Arizona • Jacksonville, Florida • Tampa, Florida + 5 more

Conditions: Acute Respiratory Distress Syndrome, Acute Respiratory Failure With Hypoxia, Acute Respiratory Failure
Interventions: Not listed
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 2,400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 28
States / cities: Tucson, Arizona • Los Angeles, California • Jacksonville, Florida + 22 more

Search by objective public record fields.

TD-1473 Long-Term Safety (LTS) Ulcerative Colitis (UC) Study

Study of Deferasirox for Treatment of Transfusional Iron Overload in Myelodysplastic Patients

Targeting Pathways in Polycystic Ovary Syndrome (PCOS) Using Metformin (MET)

Clinical Evaluation of the CADence Device in Detection of Coronary Artery Diseases

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

The Product Surveillance Registry REVERSE Post Approval Study

Complex Sleep Apnea Syndrome (CompSAS) Resolution Study

Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS - Extension Trial

Pertuzumab and Trastuzumab as Neoadjuvant Treatment in Patients With HER2-Positive Breast Cancer

The Effect of the Interaction of Glucagon and Insulin on Endogenous Glucose Production in Humans

High-Dose or Standard-Dose Radiation Therapy and Chemotherapy With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery

Evaluate the Safety and Immunogenicity of a Seasonal Influenza Virus-Like Particle (VLP) Vaccine in Older Adults

Platelet-rich Plasma for Thumb Carpometacarpal Joint Osteoarthritis

Hypofractionated Radiation Therapy or Conventional Radiation Therapy After Surgery in Treating Patients With Prostate Cancer

Spineology Clinical Outcomes Trial: An IDE Investigation

Intraperitoneal Versus Extraperitoneal Colostomy

Pivotal Study of the NanoKnife System for the Ablation of Prostate Tissue

The TOGETHER Project - Kidney

Exosome-based Omic Signatures of Disease Activity in Cardiac Sarcoidosis (EXODACS)

An Extension Study of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Duodenitis

OMEGA: Outcome Measures in Eosinophilic Gastrointestinal Disorders Across the Ages

FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC

A Study of Lirafugratinib in Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement

Severe ARDS: Generating Evidence